Teva Pharm: Copaxone significantly reduced brain atrophy and tissue loss over five years in treatment-naive relapsing-remitting multiple sclerosis patients (46.36 -0.19) -Update-
Co announces final results from a five-year comparative imaging study examining the long-term effect of disease-modifying therapies in treatment-naive, early relapsing-remitting multiple sclerosis patients, demonstrated that Copaxone treated patients experienced significantly less brain tissue loss, as measured by percent change in brain volume, compared with patients on other DMTs.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.